Abstract
Smallpox, caused by variola virus (VARV), is a devastating human disease that affected millions worldwide until the virus was eradicated in the 1970 s. Subsequent cessation of vaccination has resulted in an immunologically naive human population that would be at risk should VARV be used as an agent of bioterrorism. The development of antivirals and improved vaccines to counter this threat would be facilitated by the development of animal models using authentic VARV. Towards this end, cynomolgus macaques were identified as adequate hosts for VARV, developing ordinary or hemorrhagic smallpox in a dose-dependent fashion. To further refine this model, we performed a serial sampling study on macaques exposed to doses of VARV strain Harper calibrated to induce ordinary or hemorrhagic disease. Several key differences were noted between these models. In the ordinary smallpox model, lymphoid and myeloid hyperplasias were consistently found whereas lymphocytolysis and hematopoietic necrosis developed in hemorrhagic smallpox. Viral antigen accumulation, as assessed immunohistochemically, was mild and transient in the ordinary smallpox model. In contrast, in the hemorrhagic model antigen distribution was widespread and included tissues and cells not involved in the ordinary model. Hemorrhagic smallpox developed only in the presence of secondary bacterial infections – an observation also commonly noted in historical reports of human smallpox. Together, our results support the macaque model as an excellent surrogate for human smallpox in terms of disease onset, acute disease course, and gross and histopathological lesions.
Highlights
Smallpox is widely regarded as a scourge of epic proportions whose history dates back to ca.1350 BCE when smallpox spread from the Egyptians to the Hittites in Syria [1]
We previously described a cynomolgus macaque model for smallpox
Understanding the progression of disease will help to identify potential time points for therapeutic intervention, as well as fulfill requirements of the US Food and Drug Administration (FDA) Animal Efficacy Rule established to facilitate the acceptance of animal models for drug efficacy testing
Summary
Smallpox is widely regarded as a scourge of epic proportions whose history dates back to ca.1350 BCE when smallpox spread from the Egyptians to the Hittites in Syria [1]. BCE when smallpox spread from the Egyptians to the Hittites in Syria [1] It has been recorded throughout human history with the last naturally occurring cases being reported in 1975 in the Indian subcontinent and in 1977 in the Horn of Africa [1]. Following eradication, the USSR developed VARV as a strategic bioweapon [7,8], and concerns remain that VARV has the potential to be used as an agent of bioterrorism. For this reason, improved countermeasures against smallpox including new vaccines and antiviral drugs are urgently needed
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.